AG
VRTX icon

Ascent Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Ascent Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Sell
4,410
-1,085
-20% -$506K 0.07% 254
2025
Q4 		$2.49M Sell
5,495
-1,124
-17% -$484K 0.09% 215
2025
Q3 		$2.59M Sell
6,619
-2,033
-23% -$850K 0.09% 203
2025
Q2 		$3.85M Sell
8,652
-790
-8% -$364K 0.15% 139
2025
Q1 		$4.58M Sell
9,442
-1,345
-12% -$627K 0.2% 111
2024
Q4 		$4.34M Sell
10,787
-9
-0.1% -$4.17K 0.33% 78
2024
Q3 		$5.02M Buy
10,796
+1,763
+20% +$847K 0.38% 56
2024
Q2 		$4.23M Buy
9,033
+416
+5% +$181K 0.34% 65
2024
Q1 		$3.6M Sell
8,617
-4,759
-36% -$2.01M 0.32% 76
2023
Q4 		$5.6M Buy
13,376
+1,612
+14% +$595K 0.53% 38
2023
Q3 		$4.34M Buy
11,764
+38
+0.3% +$13.3K 0.48% 44
2023
Q2 		$4.04M Buy
11,726
+3,239
+38% +$1.09M 0.45% 46
2023
Q1 		$2.67M Buy
8,487
+3,522
+71% +$1.06M 0.28% 87
2022
Q4 		$1.43M Buy
4,965
+671
+16% +$205K 0.17% 174
2022
Q3 		$1.34M Buy
4,294
+3,186
+288% +$917K 0.16% 171
2022
Q2 		$311K Buy
+1,108
New +$297K 0.04% 382

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ascent Group's VRTX Position: Q1 2026 in Review

Ascent Group reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q1 2026, selling an estimated $506K and leaving 4,410 shares worth $1.97M. The position accounts for 0.07% of the portfolio, ranked #254.

Ascent Group first reported a position in VRTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $5.6M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ascent Group held 4,410 shares of Vertex Pharmaceuticals worth $1.97M as of Q1 2026.
  • Ascent Group sold 1,085 Vertex Pharmaceuticals shares in Q1 2026, an estimated $506K.
  • Vertex Pharmaceuticals made up 0.07% of Ascent Group's portfolio in Q1 2026, its #254 holding.
  • Ascent Group first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Ascent Group's Vertex Pharmaceuticals position peaked at $5.6M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.